IM Cannabis (IMCC) Prnewswire·2025-01-17 12:00Auditor Change - IM Cannabis Corp changed its auditor from Kost Forer Gabbay & Kasierer (member of Ernst & Young Global) to Fahn Kanne & Co Grant Thornton Israel effective January 16, 2025 [1] - The change was made at the company's request and approved by the board of directors based on the audit committee's recommendation [1] - The predecessor auditor resigned on the same date and the successor auditor will serve until the next annual shareholders meeting [1] - No reservations, modified opinions or reportable events were noted in the predecessor auditor's reports for the most recent financial year or subsequent periods [2] Company Overview - IM Cannabis Corp is an international cannabis company operating in Israel and Germany, two of the largest medical cannabis markets [3] - The company focuses on sustainable and profitable growth in these high-value markets through a data-driven approach and global supply chain [3] - In Israel, the company operates through subsidiaries that import, distribute and retail medical cannabis, supported by proprietary data and patient insights [4] - The Israeli ecosystem includes retail pharmacies, online platforms, distribution centers and logistical hubs to ensure safe delivery and quality control [4] - In Germany, the company operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical patients [4] Business Strategy - The company is committed to responsible growth and compliance with strict regulatory environments [3] - It aims to amplify commercial and brand power to become a global high-quality cannabis player [3] - The company leverages a transnational ecosystem powered by data and global supply chains [3] - It focuses on sustainable profitability while driving growth in the German market [5]